Dashboard PDUFA PDUFA History Dilution Watch Downside Radar Missed Milestones Earnings Big Movers Blog

🎤 Upcoming Biotech Conferences

Loading conferences...
Free to browse, no account needed Track ALT with free AI briefings, catalyst countdowns, and dilution alerts.

ALT · Altimmune, Inc.

Company guidance, FDA catalysts, dilution risk and cash runway, built from SEC, FDA and ClinicalTrials.gov filings and updated every day.

$479.9M Cash on Hand
46.5mo Cash Runway
Follow ALT by email Get an email when ALT reports key news in an SEC filing, pushes back a promised milestone, files for a stock offering, lands on the Downside Radar or has an FDA decision. Free, no account needed.

We send one confirmation email first. Only emails about ALT, unsubscribe in one click. Privacy

📣 What ALT Says Is Next

Quoted word for word from the company's press releases filed with the SEC. Timing is the company's own guidance, not a BioRadar estimate.

📄 Latest SEC Filings in Plain English

Each summary is written by AI from the filing itself, and one that names a number or a name the filing does not contain is not shown. Quarterly and annual reports are listed by period. Read the filing before acting on it.

🧪 Trial & FDA Catalysts

📊 Drug Pipeline

DrugIndicationMost advanced trialStatus
Licensed seasonal influenza vaccine Influenza Phase 4 · NCT03163342 Completed
Pemvidutide Metabolic Dysfunction-Associated Steatohepatitis (MASH) Phase 3 · NCT07795164 Recruiting
HepTcell Hepatitis B, Chronic Phase 2 · NCT04684914 Terminated
NasoVAX Influenza Phase 2 · NCT03232567 Completed
AdCOVID Healthy Volunteers Phase 1 · NCT04679909 Completed
Atorvastatin NASH - Nonalcoholic Steatohepatitis Phase 1 · NCT04972396 Completed
BioThrax Healthy Volunteers Phase 1 · NCT03352466 Completed
Ethinyl Estradiol NASH - Nonalcoholic Steatohepatitis Phase 1 · NCT04972396 Completed
FP-02.2 Vaccine Hepatitis B Phase 1 · NCT02496897 Completed
Metformin NASH - Nonalcoholic Steatohepatitis Phase 1 · NCT04972396 Completed
NasoShield Healthy Volunteers Phase 1 · NCT04415749 Completed
Pandemic Influenza Vaccine Influenza A Subtype H5N1 Infection Phase 1 · NCT00755703 Completed
Warfarin NASH - Nonalcoholic Steatohepatitis Phase 1 · NCT04972396 Completed
Subjects were administered NasoVAX high dose Influenza N/A · NCT03760549 Completed

Also used in these trials (approved or third-party drugs, not ALT's own candidates): IL-2 Recombinant Fusion Protein ALT-801, Digoxin.

Source: ClinicalTrials.gov trials sponsored by the company, one row per candidate at its most advanced registered trial. FDA approvals: Drugs@FDA. Wrong or missing drug? Report it

💰 Cash Runway & Dilution Risk

ALT holds $479.9M in cash and short-term investments (as of Sep 30, 2026) and burns about $31M/quarter from operations, an estimated runway of 46.5 months at that rate (BioRadar estimate, not company guidance).

Dilution pressure: 45 · Elevated

Recent financing filings on SEC EDGAR:

Source: SEC EDGAR (XBRL cash flow and financing filings). Dilution Watch: every company ranked → · Get an alert when ALT files for a raise →

👥 Who Owns ALT

Insiders 0.5% Other 5%+ holders 6.9% Institutions (274 holders) 78.1% Public and other holders 14.5%
HolderTypeShares% of sharesAs of
Deep Track Capital, LP Institution (13G, 5%+) 19,417,221 9.98% 2026-04-23
VIKING GLOBAL INVESTORS LP 5%+ holder (13G) 13,400,000 6.89% 2026-04-24
RA Capital Management, L.P. Institution (13G, 5%+) 13,000,000 6.68% 2026-04-24
Vipin K Garg
Director · +26,775 options
Insider 424,519 0.22% 2026-01-30
M Scot Roberts
Chief Scientific Officer · +318,100 options
Insider 113,699 0.06% 2026-07-31
Jerome Benedict Durso
President and CEO, Director · +2.46M options
Insider 93,200 0.05% 2026-11-13
Gregory L Weaver
Chief Financial Officer · +463,300 options
Insider 73,005 0.04% 2026-11-13
Raymond M Jordt
Chief Business Officer · +47,550 options
Insider 70,107 0.04% 2026-01-31
Wayne Pisano
Director · +48,800 options
Insider 58,800 0.03% 2026-11-13
Christophe Arbet-Engels
Chief Medical Officer · +562,500 options
Insider 24,821 0.01% 2026-10-01
John Gill
Director · +48,800 options
Insider 21,700 0.01% 2026-04-06
Linda M Richardson
Chief Commercial Officer · +72,000 options
Insider 17,174 0.01% 2026-09-16

Share count 194,589,451 (latest 10-Q/10-K). Insiders: each officer's, director's and 10% owner's latest Form 3, 4 or 5, direct and indirect shares; options are not counted. 5%+ holders: latest Schedule 13D or 13G of each holder above 5%. Institutions: the total held by all 13F filers (Yahoo Finance); the table lists the largest. Sources have different dates, so the split is approximate. Source: SEC EDGAR.

Get the full ALT picture

The 7-day free trial adds AI daily briefings, sentiment tracking, trial enrollment progress and email alerts for ALT and every other ticker you follow. Card required, cancel anytime.

Start 7-day free trial →

Data: SEC EDGAR, FDA, ClinicalTrials.gov, Yahoo Finance • Informational purposes only, not investment advice. • All tracked stocks A–Z

This data is for informational purposes only, not investment advice. BioRadar does not provide buy/sell recommendations. Past performance does not guarantee future results. Always do your own due diligence.